Athira Says Phase II Alzheimer’s Miss Will Inform Ongoing Phase III Study

Athira hoped a small Phase II study would show a benefit on working memory processing speed, but it missed its primary and all secondary endpoints, reducing confidence in the Phase III program.

Alzheimers_677117191_Atthapon-Raksthaput_1200.jpg
Athira faces a setback for its mechanism against Alzheimer's disease

More from Clinical Trials

More from R&D